IP Library Granted Patent US 10,697,017
Granted Patent B2
US 10,697,017 · App. 14/367,510 · Granted Jun 30, 2020

Genetic factors in blood pressure

Inventors: Sophie Visvikis-Siest (Nancy, FR); Said El Shamieh (Nancy, FR); Helena Murray (Crumlin, GB); John Lamont (Crumlin, GB); Peter Fitzgerald (Crumlin, GB)
Assignee: RANDOX LABORATORIES LTD.
C12Q1/6883C12Q2600/106C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,697,017
App. No.
14/367,510
Granted
Jun 30, 2020
Kind
B2
Abstract

The invention describes epistatic interactions between single nucleotide polymorphisms on genes associated with blood pressure and provides an application for their use in a method to determine an individual's susceptibility to hypertension and hence whether anti-hypertensive treatment will be beneficial for said individual. In addition gene expression levels are also linked to blood pressure and may also be used to determine susceptibility to hypertension.

Claims (8)

1. A method of treating an individual predisposed to high blood pressure comprising:

(a) obtaining a biological sample from the individual, wherein the individual has not been treated with antihypertensive drug therapy;

(b) determining whether a rs5355C>T single nucleotide polymorphism in the SELE gene is present or absent in the biological sample by contacting the biological sample with a nucleic acid probe that hybridizes to the rs5355C>T single nucleotide polymorphism, wherein the rs5355C>T single nucleotide polymorphism is determined to be present;

(c) determining whether a rs6046G>A single nucleotide polymorphism in the F7 gene is present or absent in the biological sample by contacting the biological sample with a nucleic acid probe that hybridizes to the rs6046G>A single nucleotide polymorphism, wherein the rs6046G>A single nucleotide polymorphism is determined to be present;

(d) after said determining of (b) and (c), determining the individual is predisposed to high blood pressure; and

(e) administering to the individual determined to have both the rs5355C>T and rs6046G>A single nucleotide polymorphism an anti-hypertensive therapy selected from the group consisting of a calcium channel blocker, renin-angiotensin system inhibitor, diuretic, adrenergic receptor antagonist, aldosterone antagonist, vasodilator, and alpha-2 agonist.

2. The method of claim 1 , wherein the biological sample of (a) is selected from the group consisting of whole blood, serum, plasma, urine, saliva, tissue sample, and hair.

3. The method of claim 1 , wherein said determining of (b) and (c) is conducted with an assay selected from among DNA microarray, polymerase chain reaction, and fluorescent in-situ hybridization.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVENYANCE PREVIOUSLY RECORDED AT REEL: 055950 FRAME: 0471. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Apr 20, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 056210/0055 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2021
From: RANDOX LABORATORIES LIMITED
To: NORTHERN BANK LIMITED
Reel/Frame 055950/0471 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 30, 2015
From: VISVIKIS-SIEST, SOPHIE; EL SHAMIEH, SAID; MURRAY, HELENA; LAMONT, JOHN V.; FITZGERALD, PETER
To: RANDOX LABORATORIES LTD.
Reel/Frame 035538/0537 →